Extended rituximab therapy in Waldenström's macroglobulinemia
نویسندگان
چکیده
منابع مشابه
Extended rituximab therapy in Waldenström's macroglobulinemia.
BACKGROUND Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma. Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m(2)/week. METHODS In an effort to increase rituximab activity in WM, an extended dose schedul...
متن کاملInterstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
Rituximab-combined therapeutic regimens have been recommended for treatment of Waldenström's Macroglobulinemia (WM). We report one WM patient who developed interstitial pneumonitis after rituximab therapy.
متن کاملLenalidomide and rituximab in Waldenstrom's macroglobulinemia.
PURPOSE Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent. EXPERIMENTAL DESIGN Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1...
متن کاملNimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
Neem leaf extract (NLE) has medicinal properties, which have been attributed to its limonoid content. We identified the NLE tetranorterpenoid, nimbolide, as being the key limonoid responsible for the cytotoxicity of NLE in various preclinical models of human B-lymphocyte cancer. Of the models tested, Waldenströms macroglobulinemia (WM) cells were most sensitive to nimbolide, undergoing signific...
متن کاملDiagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
Waldenströms macroglobulinemia (WM) is a B-cell malignancy characterized by high level of monoclonal immunoglobulin M (IgM) paraprotein in blood serum and associated with the bone marrow infiltration by malignant cells with lymphoplasmacytic differentiation. WM remains incurable advances in therapy. Most of WM cases are associated with a somatic point mutation L265P in MYD88. Significantly high...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2005
ISSN: 0923-7534
DOI: 10.1093/annonc/mdi022